Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (E)-5-((3-carboxy-4-hydroxyphenyl)diazenyl)-2-hydroxybenzoic-1,2,3,4,5,6-13C6 acid
Purity: ≥98%
Formula Markup: C8[13C]6H10N2O6
Formula Weight: 308.2
Notes: Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine (Item No. 23661) by GC- or LC-MS. Olsalazine is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA; Item No. 70265) that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.{30379} In vitro, olsalazine increases ion transport in isolated rabbit distal ileum when applied to the luminal side (ED50 = 0.3 mM) and stimulates fluid transport in rat jejunum when used at a concentration of 5 mM.{41622,41623} Olsalazine (150 mg/kg for 8 days) improves stool consistency and decreases occult and gross bleeding as well as myeloperoxidase (MPO) activity and leukotriene B4 (LTB4; Item No. 20110) levels in colon tissue in a mouse model of acute colitis induced by dextran sulfate (Item No. 23250).{41624} Olsalazine also inhibits bovine xanthine oxidase in vitro (IC50 = 3.4 mg/L) and lowers serum uric acid levels in a mouse model of hyperuricemia induced by oxonic acid (Item No. 22586) when administered at a dose of 20 mg/kg.{41625} Formulations containing olsalazine have been used in the treatment of inflammatory bowel disease (IBD) and ulcerative colitis.
English
Deutsch
